RITUXILUP
Trial Details
- Trial statusFollowup
- Study email contactrituxilup@imperial.ac.uk
- Chief InvestigatorProfessor Liz Lightstone
- Project managerRobert Niesiolowski
- SponsorImperial College London
- ISRCTN number84054592
- PhaseIII
- View clinicaltrials.gov website
An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis
Design and Objective
There is evidence to suggest that a drug called Rituximab may be a safe and effective treatment of lupus nephritis when used with MMF but without oral corticosteroids, therefore the purpose of this study is to investigate if Rituximab is effective in treating lupus nephritis when given with MMF, but without oral corticosteroids.
Key inclusion criteria
Children (12 years and above) and adults with lupus nephritis ISN/RPS Class III A or A/C, Class IV-G A or A/C, Class IV-S A or A/C, and/or Class V with a urine protein/creatinine ratio (PCR) ≥ 100mg/mmol.